Pfizer's and BioNTech's vaccine has been a phenomenal success story, from the breathtakingly fast development to the jaw-dropping efficacy. And now there's even more good news. Here's why Pfizer's and BioNTech's COVID vaccine could be even better than expected.
A new trial took place in South Africa, where the variant, known as B.1.351, first emerged. Some scientists worry that it might be able to escape existing vaccines.
In the Pfizer-BioNTech trial, six cases of the variant were observed, none of them in people who had been given the vaccine.
There have been 312 identified cases of the strain in the U.S., according to the latest figures from the CDC.
Success of the Pfizer Vaccines against South Africa variant appears to be 100 %.
Keep our fingers crossed. Just a thought.
No comments:
Post a Comment